

Marie Jachiet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/137268/publications.pdf>

Version: 2024-02-01

40
papers

1,053
citations

567281

15
h-index

434195

31
g-index

40
all docs

40
docs citations

40
times ranked

1709
citing authors

#	ARTICLE	IF	CITATIONS
1	Vascular skin symptoms in COVID-19: a French observational study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e451-e452.	2.4	225
2	Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 143-151.	1.2	159
3	Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 667-670.	1.2	144
4	Posaconazole Treatment of Extensive Skin and Nail Dermatophytosis Due to Autosomal Recessive Deficiency of CARD9. <i>JAMA Dermatology</i> , 2015, 151, 192.	4.1	71
5	UBA1 Variations in Neutrophilic Dermatoses Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 1349.	4.1	71
6	Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e74-e76.	2.4	53
7	Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1164-1172.	2.4	33
8	MDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN- β Transcript. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1276-1279.e7.	0.7	30
9	Dramatic improvement of generalized prurigo nodularis with dupilumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e303-e304.	2.4	25
10	Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2777-2779.e1.	3.8	20
11	TH cell diversity and response to dupilumab in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 756-759.	2.9	20
12	Persistent deficiency of mucosal-associated invariant T cells during dermatomyositis. <i>Rheumatology</i> , 2020, 59, 2282-2286.	1.9	19
13	Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e394-e396.	2.4	19
14	Dupilumab-induced psoriasis and alopecia areata: Case report and review of the literature. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 198-201.	1.0	19
15	Cutaneous Adverse Drug Reaction to Oral Acetazolamide and Skin Tests. <i>Dermatology</i> , 2013, 226, 347-352.	2.1	15
16	Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1441-1444.	1.2	15
17	Identification of clonal skin myeloid cells by next-generation sequencing in myelodysplasia cutis. <i>British Journal of Dermatology</i> , 2021, 184, 367-369.	1.5	12
18	Efficacy of dupilumab for controlling severe atopic dermatitis with dominant-negative CARD11 variant. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1334-1335.	1.3	12

#	ARTICLE	IF	CITATIONS
19	Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 945-947.	1.2	10
20	Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e566-e568.	2.4	10
21	Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity. <i>British Journal of Dermatology</i> , 2014, 171, 63-68.	1.5	9
22	Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: a French multicentre retrospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1446-1448.	0.9	8
23	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103034.	5.8	8
24	Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B-cell lymphoma presenting as AL amyloidoma of the skin. <i>British Journal of Dermatology</i> , 2019, 181, 607-609.	1.5	7
25	Treatment of Eosinophilic Annular Erythema: Retrospective multicenter study and literature review. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 123-127.	1.0	6
26	Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 602-603.	1.5	6
27	Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 681-684.	1.2	5
28	Low cardiovascular risk and poor quality of life associated with tobacco use and skin infections in adult atopic dermatitis: result of a French multicenter study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e451-e453.	2.4	4
29	Sleep disturbance in atopic dermatitis: a case-control study using actigraphy and smartphone-collected questionnaires. <i>British Journal of Dermatology</i> , 2020, 183, 577-579.	1.5	3
30	Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice. <i>British Journal of Dermatology</i> , 2022, 186, 733-735.	1.5	3
31	Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
32	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. <i>BMC Nephrology</i> , 2022, 23, 67.	1.8	3
33	Cutis laxa for diagnosis of λ^3 heavy chain deposition disease: Report of four cases. <i>Journal of Dermatology</i> , 2018, 45, 1211-1215.	1.2	2
34	Hypothyroidism revealed by acquired ichthyosis in an adult patient. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 130-132.	1.0	2
35	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 872-872.	5.6	1
36	Increased CD8+CD28- circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2019, 85, 755-758.	1.2	1

#	ARTICLE	IF	CITATIONS
37	Asymmetric red-blue hypertrophic hand and tenosynovitis due to acrodermatitis chronica atrophicans. <i>Rheumatology</i> , 2019, 58, 655-655.	1.9	0
38	Acropulpsitis in systemic lupus erythematosus is associated with high type 1 interferon signature. <i>Experimental Dermatology</i> , 2022, 31, 819-820.	2.9	0
39	Legã€type form of idiopathic multicentric Castleman disease associated with severe lower extremity chronic venous/lymphatic disease. <i>EJHaem</i> , 2022, 3, 175-179.	1.0	0
40	Perioral skin thickening revealing <sc>AL</sc> amyloidosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	0